Alembic Pharmaceuticals is currently trading at Rs. 94.15, up by 1.95 points or 2.11% from its previous closing of Rs. 92.20 on the BSE.
The scrip opened at Rs. 93.20 and has touched a high and low of Rs. 96.70 and Rs. 92.40 respectively. So far 468772 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 96.70 on 06-Mar-2013 and a 52 week low of Rs. 41.65 on 20-Mar-2012.
Last one week high and low of the scrip stood at Rs. 96.70 and Rs. 80.00 respectively. The current market cap of the company is Rs. 1811.64 crore.
The promoters holding in the company stood at 74.13% while Institutions and Non-Institutions held 7.76% and 18.11% respectively.
Alembic Pharmaceuticals has received approval from the USFDA for its NDA, Desvenlafaxine Base Extended Release (ER) Tablets, a bioequivalent version of innovator drug, Pristiq by Pfizer. The company is the sponsor and manufacturer of the NDA. Desvenlafaxine Base Extended Release Tables is Alembic's first 505 (b) (2) filing.
Further, the company has entered into an out-licensing arrangement with Ranbaxy Pharmaceuticals Inc (Ranbaxy), a wholly owned subsidiary of Ranbaxy Laboratories for exclusively marketing the product in the United States of America. The product will be available in 50 mg and 100 mg dosage strengths. The parties will launch the product immediately.
Desvenlafaxine Base Extended Release Tablets is a prescription medicine that is indicated for the treatment of major depressive disorder. The current market size for Pristiq is approximately $ 538 million, based on industry sales data.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1804.65 |
Dr. Reddys Lab | 1209.00 |
Cipla | 1503.40 |
Lupin | 2107.30 |
Zydus Lifesciences | 964.95 |
View more.. |